MAP Pharmaceuticals (MAPP) Director Sells 100K Shares Following 300% Run-Up
More News related to MAPP
- MAP Pharmaceuticals Reports Third Quarter of 2009 Financial Results
- MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
- 'Headache' Publication Describes Potential Mechanistic Rationale for LEVADEX(TM) Favorable Adverse Event Profile
- MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
- MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
After the close, MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) Director Thomas Armer disclosed the sale of 100,000 shares from 5/26-5/27 at prices from $9-$10.01. Armer exercised options on 60,000 shares at $0.74. Armer has a remaining position of 332,403 shares following the sale. In addition, Armer indicated a 10b(5)-1 trading plan.
Shares of MAP Pharmaceuticals are up 320% since last Friday after announcing that efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX orally inhaled migraine therapy met all four primary endpoints.
Related Categories
Insider TradesMomentum Movers
Stocks Mentioned
+0.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
